Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gimsing

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Cancer Medicine|June 23, 2017
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based studyHenrik Gregersen, Annette Juul Vangsted, Niels Abildgaard, et al.
Molecular Oncology|November 14, 2017
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent mannerKonstantinos Dimopoulos, Alexandra Søgaard Helbo, Helga Fibiger Munch-Petersen, et al.
European Journal of Haematology|December 30, 2015
Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort studyRasmus Sørrig, Tobias W Klausen, Morten Salomo, et al.
Clinical Epidemiology|November 9, 2016
The Danish National Multiple Myeloma RegistryPeter Gimsing, Morten O Holmström, Tobias Wirenfelt Klausen, et al.
Plos One|December 8, 2017
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish populationRasmus Sørrig, Tobias W Klausen, Morten Salomo, et al.
British Journal of Haematology|June 10, 2020
Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registryLouise Redder, Tobias W Klausen, Annette Juul Vangsted, et al.
British Journal of Haematology|April 29, 2006
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study GroupStig Lenhoff, Martin Hjorth, Jan Westin, et al.
Blood|June 15, 2011
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trialsPeter M Fayers, Antonio Palumbo, Cyrille Hulin, et al.
American Journal of Hematology|May 5, 2018
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaXavier Leleu, Tamas Masszi, Nizar J Bahlis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple MyelomaMarkus Hansson, Peter Gimsing, Ashraf Badros, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Cancer Medicine|June 23, 2017
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based studyHenrik Gregersen, Annette Juul Vangsted, Niels Abildgaard, et al.
Molecular Oncology|November 14, 2017
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent mannerKonstantinos Dimopoulos, Alexandra Søgaard Helbo, Helga Fibiger Munch-Petersen, et al.
European Journal of Haematology|December 30, 2015
Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort studyRasmus Sørrig, Tobias W Klausen, Morten Salomo, et al.
Clinical Epidemiology|November 9, 2016
The Danish National Multiple Myeloma RegistryPeter Gimsing, Morten O Holmström, Tobias Wirenfelt Klausen, et al.
Plos One|December 8, 2017
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish populationRasmus Sørrig, Tobias W Klausen, Morten Salomo, et al.
British Journal of Haematology|June 10, 2020
Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registryLouise Redder, Tobias W Klausen, Annette Juul Vangsted, et al.
British Journal of Haematology|April 29, 2006
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study GroupStig Lenhoff, Martin Hjorth, Jan Westin, et al.
Blood|June 15, 2011
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trialsPeter M Fayers, Antonio Palumbo, Cyrille Hulin, et al.
American Journal of Hematology|May 5, 2018
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaXavier Leleu, Tamas Masszi, Nizar J Bahlis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple MyelomaMarkus Hansson, Peter Gimsing, Ashraf Badros, et al.
Pageof 6